Galaviz RAP, Soto RI, Segura LFK, Muñoz HMA, García AFJ, Sicsik ASA

Language: Spanish
References: 21
Page: 479-487
PDF size: 206.55 Kb.

ABSTRACT

Objective: To determine the frequency of renal relapse after remission induction treatment in subjects with proliferative lupus nephritis treated at a tertiary center.
Materials and Methods: Single-center observational retrospective cohort study of patients with a clinical diagnosis of systemic lupus erythematosus according to the SLICC 2012 criteria and pathological diagnosis of class III and IV lupus nephritis who received remission induction therapy from January 2020 to December 2022 at the UMAE 71 Specialty Hospital in the city of Torreon, Coahuila, Mexico.
Results: Sixty-eight files that met the inclusion criteria were included. Of the 20 patients treated with cyclophosphamide, 6 presented a complete response vs 27 of 48 who received mycophenolate mofetil (p = 0.0424). Out of 19 cases treated with high doses of cyclophosphamide, 4 presented nephritis relapse, as well as 2 of 48 patients treated with mycophenolate mofetil (p = 0.05).
Conclusions: Patients with class III/IV lupus nephritis obtain greater benefit with mycophenolate mofetil during induction therapy.

REFERENCES

1. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupusnephritis: Core Curriculum 2020. Am J Kidney Dis 2020; 76:265-81.doi: 10.1053/j.ajkd.2019.10.017

2. Tamirou F, Houssiau FA. Management of lupus nephritis.J Clin Med 2021; 10: 1-11. doi: 10.3390/jcm10040670

3. De Rosa M, Azzato F, Toblli JE, De Rosa G, et al. A prospectiveobservational cohort study highlights kidney biopsyfindings of lupus nephritis patients in remission who flarefollowing withdrawal of maintenance therapy. Kidney Int2018; 94. doi: 10.1016/j.kint.2018.05.021

4. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ,et al. Remission and Low Disease Activity Status (LDAS)protect lupus patients from damage occurrence: datafrom a multiethnic, multinational Latin American LupusCohort (GLADEL). Ann Rheum Dis 2017; 76. doi: 10.1136/annrheumdis-2017-211814

5. Gul H, Mushtaq MS, Salim B, Samreen S, et al. A Comparisonof mycophenolate mofetil and cyclophosphamide aslupus nephritis induction therapy. J Ayub Med Coll Abbottabad2020; 32: 454-8.

6. Liu Z, Zhang H, Liu Z, Xing C, et al. Multitarget therapy forinduction treatment of lupus nephritis: a randomized trial:A randomized trial. Ann Intern Med 2015; 162: 18-26. doi:10.7326/M14-1030

7. Chen YE, Korbert SM, Katz RS, Schwartz MM, et al. Value ofa complete or partial remission in severe lupus nephritis.Clin J Am Soc Nephrol 2008; 3. doi: 10.2215/CJN.03280807

8. Weeding E, Fava A, Magder L, Goldman D, Petri M. Onethirdof patients with lupus nephritis classified as completeresponders continue to accrue progressive renal damagedespite resolution of proteinuria. Lupus Sci Med 2022; 9.doi: 10.1136/lupus-2022-000684

9. Wang J, Qi YY, Chen XP, Ma L, et al. Analysis of clinical riskfactors in relapsed patients with class IV lupus nephritis.Exp Ther Med 2018; 15. doi: 10.3892/etm.2018.6130

10. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupusnephritis: Clinical presentations and outcomes in the 21stcentury. Rheumatology (United Kingdom) 2020; 59: V39-51. doi: 10.1093/rheumatology/keaa381

11. Ichinose K, Kitamura M, Sato S, Eguchi M, et al. Completerenal response at 12 months after induction therapy is associatedwith renal relapse-free rate in lupus nephritis: asingle-center, retrospective cohort study. Lupus 2019; 28:501-9. doi: 10.1177/0961203319829827

12. Sprangers B, Monahan M, Appel GB. Diagnosis and treatmentof lupus nephritis flares--an update. Nat Rev Nephrol2012; 8: 709-17. doi: 10.1038/nrneph.2012.220

13. Illei GG, Takada K, Parkin D, Austin HA, et al. Renal flaresare common in patients with severe proliferative lupusnephritis treated with pulse immunosuppressive therapy:long-term followup of a cohort of 145 patients participatingin randomized controlled studies. Arthritis Rheum 2002;46: 995-1002. doi: 10.1002/art.10142

14. Yap DYH, Tang C, Ma MKM, Mok MMY, et al. Longtermdata on disease flares in patients with proliferative lupusnephritis in recent years. J Rheumatol 2017; 44: 1375-83.doi: 10.3899/jrheum.170226

15. Tunnicliffe DJ, Palmer SC. Immunosuppressive treatmentfor proliferative lupus nephritis: Summary of a CochraneReview. Am J Kidney Dis 2018; 72. doi: 10.1053/j.ajkd.2018.07.008

16. So MW, Koo BS, Kim Y-G, Lee C-K, Yoo B. Predictive valueof remission status after 6 months induction therapy inpatients with proliferative lupus nephritis: a retrospectiveanalysis. Clin Rheumatol 2011; 30: 1399-405. doi: 10.1007/s10067-011-1778-2

17. Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as apredictor of incident and progressive CKD in patients withlupus nephritis. Clin J Am Soc Nephrol 2014; 9: 279-84. doi:10.2215/CJN.05040513

18. Mosca M, Bencivelli W, Neri R, Pasquariello A, et al.Renal flares in 91 SLE patients with diffuse proliferativeglomerulonephritis. Kidney Int 2002; 61: 1502-9. doi:10.1046/j.1523-1755.2002.00280.x

19. Hill GS, Delahousse M, Nochy D, Rémy P, et al. Predictivepower of the second renal biopsy in lupus nephritis: significanceof macrophages. Kidney Int 2001; 59: 304-16.doi: 10.1046/j.1523-1755.2001.00492.x

20. Yang T-H, Wu T-H, Chang Y-L, Liao H-T, et al. Cyclosporine forthe treatment of lupus nephritis in patients with systemiclupus erythematosus. Clin Nephrol 2018; 89: 277-85. doi:10.5414/CN109325

21. Rovin BH, Furie R, Latinis K, Looney RJ, et al. Efficacy andsafety of rituximab in patients with active proliferativelupus nephritis: the Lupus Nephritis Assessment withRituximab study. Arthritis Rheum 2012; 64: 1215-26. doi:10.1002/art.34359